Differences Between Interferon-alpha and -beta for Patients with HCV

TITLE: Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

To compare virological, biochemical, and immune responses to human lymphoblastoid interferon (IFN-alpha) and human fibroblast interferon (IFN-beta) in patients with chronic hepatitis C virus (HCV) infection, 120 patients were randomly assigned to three groups (group A, 60 patients receiving IFN-alpha, 6 million units (MU) once a day, daily for one month and thrice weekly for five months; group B, 40 patients receiving 6 MU IFN-beta once a day daily for two months; and group C, 20 patients receiving 3 MU IFN-beta twice a day (6 MU/day) daily for two months). Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Patients with sustained clearance of serum HCV RNA detected by polymerase chain reaction (PCR) at six months after IFN treatment were defined as having complete response to IFN treatment. A low level of HCV RNA (less than or = 10(4) copies/50 microl, measured by competitive PCR) and HCV RNA of genotype 2a were favorable factors for a complete response to both IFNs. Complete response in group A treatment was strongly associated with early HCV RNA clearance, in contrast with group B. A significantly higher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0%), compared with groups A (41.6%) and B (27.5%). sIL-2R levels rose in each group during IFN administration. In group C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findings indicate that timing of serum HCV RNA negativity in sustained response differs between IFN-alpha and IFN-beta administrations and that early HCV RNA clearance was induced by twice-a-day IFN-beta treatment.

AUTHOR: Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, Ariyama I, Kinukawa N, Kashiwagi S, Department of General Medicine and Medical Informatics, Kyushu University Hospital, Fukuoka, Japan.
SOURCE: Dig Dis Sci 1999 Mar;44(3):608-17

Advertisement
Hepatitis C Primer Home

What is Hepatitis How is Hepatitis Transmitted

Long-term Prognosis

Complications of HCV Liver Biopsy Treatment Info (Interferon, Herbal, etc) Lab Tests (PCR, Genotype,etc.) Nutrition & Alternative Info

Patient Information (Support Groups, Doctor Listing, etc) Related Webpages Transplant Info Site Search HCV Webrings Guestbook FAQ & Disclaimers

Anemia and Hepatitis C Treatment
In opposition to what seems logical, research demonstrates that becoming anemic while on Hepatitis C therapy is not such a bad thing.

Bristol-Myers Gains Momentum with All-Oral Hep C Therapy
In a recent study, over one third of previous non-responders cleared Hepatitis C with an interferon-free combo of two Bristol-Myers experimental drugs.

Hepatitis C Gains Access to Brain Cells
Helping to explain why Hepatitis C can cause extrahepatic manifestations (problems outside of the liver), American researchers confirmed that certain brain cells are susceptible to the Hepatitis C virus.

More Hep C articles ...